INTERNATIONAL BUSINESS ANALYSIS ON

BEXIMCO PHARMACEUTICALS
NAME

Ehsan Karim
Kasmin Younus
MD. Nawaz Sharif Tanvir
Mumtahena Khorshed
Faria Ejaj
Abhishek Nandi
Ayesha Iqbal Pinky
Palida Afrin

ID

101 0347 030

112 0049 030
111 0411 030
111 1034 030
111 0559 530
111 0923 030
111 0365 030
111 0549 030

COMPANY OVERVIEW
Beximco Pharmaceuticals is one of the largest exporters of
medicines in Bangladesh, winning National Export (Gold) Trophy for
a record three times
BPL mainly use the low cost strategy for international business,
their focus on cost leadership with broader target as a competitive
scope
Hong Kong (Export), Russia (Export), Singapore (Strategic Alliance),
Pakistan (WHS), Myanmar (Export), Afghanistan & Soloman Island
(WHS), Kenya (WHS), South Africa & Netherlands (Contract) etc.
322 products registered in Asia, 91 in Africa, five in Central and
Latin America, and 22 in Middle East

COUNTRY 1: SINGAPORE
HDI Index: 0.901 => Ranking 9th (2014)
Future growth of Singapore will be even higher with current businesslocation growth strategy while meeting the expectations of an affluent
and rapidly ageing society
knowledge-based economy (KBE) and targeting for new niches
Currently facing ageing demographics, economic restructuring and a
current economic slowdown and it is certainly a paternalistic one
free-enterprise economy with average tariff rate of 0 percent, and there
are few non-tariff barriers
global standardization strategy => pressure for cost reduction is quiet
high & pressure for qualities and measurement standards for drug
supplies

COUNTRY 2: HONG KONG

BPL started its first exports of API to Hong Kong in 1992
HDI Index: 0.892 => Ranking 15th (2014)
Future growth is stable but rapid economic growth by expanding domestic
demand with social development strategy by upgrading social services
knowledge-based economy (KBE) and being collectivist by a number of studies
Hong Kong has been ranked as the world's freest economy for the past 18 years
economic, social and political development, the Hong Kong government is
expected to become more interventionist
free-enterprise economy with 0 percent average tariff rate and few barriers to
foreign investment and no restrictions on foreign banks
global standardization strategy => pressure for cost reduction is quiet high &
pressure for qualities and measurement standards for drug supplies

COUNTRY 3: MYANMAR
HDI Index: 0.524 => Ranking 150th (2014)
With underdeveloped institutional capabilities, poor revenue performance has led to
persistent fiscal deficits, which have been financed by the central bank
Myanmar has transitioned from a direct military dictatorship to a formally
democratic system and has embarked on a period of rapid economic reform
Political economy of Myanmars dual transition from state socialism to capitalism
and from dictatorship to democracy
Government has promised to pursue a course of political and economic
liberalization, corruption remains pervasive
Myanmars average tariff rate is 3.2 percent; Numerous non-tariff barriers further
impede trade where state-owned banks dominate the underdeveloped financial
sector
New foreign investment law and international strategy where pressure for cost is
low with less responsiveness to local pressures